License Agreements - Additional Information (Details) - USD ($)		1 Months Ended			3 Months Ended		12 Months Ended
	Jul. 13, 2021	Mar. 31, 2021	Jan. 31, 2021	Mar. 31, 2019	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Jan. 31, 2022
License and Other Revenue
Research And Development Arrangement Contract To Perform For Others [Line Items]
Revenue					$ 16,000	$ 25,500,000
George Washington
Research And Development Arrangement Contract To Perform For Others [Line Items]
Percentage of royalty on net sales					6.00%
Percentage of payments received from sublicensee					15.00%
Royalty payments					$ 600,000	2,800,000
Harvard
Research And Development Arrangement Contract To Perform For Others [Line Items]
Percentage of royalty on net sales					5.00%
Percentage of payments received from sublicensee					20.00%
Clinical development and regulatory milestones amount payable					$ 15,100,000
Percentage of minimum royalty rate					4.50%
Percentage of maximum royalty based on achievement of annual net product sales thresholds					7.50%
Royalty payments					$ 100,000	100,000
Payments related to clinical development and regulatory milestones					0	$ 0
Paratek
Research And Development Arrangement Contract To Perform For Others [Line Items]
Percentage of royalty on net sales				2.25%
Royalty payments					$ 100,000
Claim expiration					2023-10
PAION AG
Research And Development Arrangement Contract To Perform For Others [Line Items]
Upfront cash payment			$ 22,500,000
Milestone payment			$ 109,500,000
Percentage of refundable tax withholding			15.00%
Supply agreement term	3 years
PAION AG | Other Current Assets
Research And Development Arrangement Contract To Perform For Others [Line Items]
Percentage of refundable tax withholding			15.00%
Refundable tax withholding amount			$ 3,400,000
PAION AG | License and Other Revenue
Research And Development Arrangement Contract To Perform For Others [Line Items]
Upfront cash payment			$ 22,500,000
Everest Medicines Limited
Research And Development Arrangement Contract To Perform For Others [Line Items]
Additional regulatory milestone payments receivable					$ 8,000,000.0
Sales milestone payments receivable					$ 20,000,000.0
Royalties payable description					Royalties are payable with respect to each jurisdiction in the Everest Territory until the latest to occur of: (i) the last-to-expire of specified patent rights in such jurisdiction in the Everest Territory; (ii) expiration of marketing or regulatory exclusivity in such jurisdiction in the Everest Territory; or (iii) 10 years after the first commercial sale of a product in such jurisdiction in the Everest Territory.
Royalties payable period after first commercial sale of product					10 years
Milestone payments received		$ 3,000,000.0
Everest Medicines Limited | Commercial Supply Agreement
Research And Development Arrangement Contract To Perform For Others [Line Items]
Proceeds from upfront payments							$ 6,800,000
Proceeds from upfront technology transfer payment							4,000,000.0
Proceeds from partial prepayment for XERAVA							$ 2,800,000
Additional technology transfer payment receivable								$ 1,000,000.0
Percentage of reimbursed for direct and certain indirect manufacturing costs through December 31, 2023							110.00%
Deferred revenue					$ 2,800,000		$ 2,800,000
Everest Medicines Limited | License and Other Revenue | Commercial Supply Agreement
Research And Development Arrangement Contract To Perform For Others [Line Items]
Revenue							$ 5,000,000.0